(Q34458514)

2 August 2017

1 reference

title

Amisulpride: a review of its use in the management of schizophrenia. (English)

1 reference

2 August 2017

0 references

M P Curran

1 reference

2 August 2017

C M Perry

series ordinal

1 reference

2 August 2017

publication date

1 January 2001

1 reference

2 August 2017

1 reference

2 August 2017

1 reference

2 August 2017

1 reference

2 August 2017

page(s)

2123-2150

1 reference

Conventional antipsychotic medications for schizophrenia

2 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200161140-00014

Treatment outcomes in schizophrenia: implications for practice, policy, and research

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200161140-00014

Overview: maintenance therapy in psychiatry: I. Schizophrenia

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200161140-00014

Clinical, EEG mapping and psychometric studies in negative schizophrenia: comparative trials with amisulpride and fluphenazine

21 January 2018

1 reference

12 December 2020

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

1 reference

12 December 2020

Amisulpride versus haloperidol in treatment of schizophrenic patients--results of a double-blind study

1 reference

12 December 2020

Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia

1 reference

12 December 2020

Tolerability of atypical antipsychotics

1 reference

12 December 2020

Effects of haloperidol and amisulpride on motor and cognitive skill learning in healthy volunteers

1 reference

12 December 2020

The costs of schizophrenia. Assessing the burden.

1 reference

12 December 2020

D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients

1 reference

12 December 2020

Psychopathology and common sense.

1 reference

12 December 2020

Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group).

1 reference

12 December 2020

Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group

1 reference

12 December 2020

In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia

1 reference

12 December 2020

Cognitive impairment in schizophrenia: its impact on social functioning

1 reference

12 December 2020

Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity

1 reference

12 December 2020

In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia

1 reference

12 December 2020

Safety and pharmacokinetics of a single oral dose of amisulpride in healthy elderly volunteers.

1 reference

12 December 2020

Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group.

1 reference

12 December 2020

Switching approach in the management of schizophrenia patients

1 reference

12 December 2020

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

1 reference

12 December 2020

Some aspects of the cost of schizophrenia in France

1 reference

12 December 2020

Effects of amisulpride, an atypical antipsychotic which blocks preferentially presynaptic dopamine autoreceptors, on integrated functional cerebral activity in the rat.

1 reference

12 December 2020

Effects of acute and repeated administration of amisulpride, a dopamine D2/D3 receptor antagonist, on the electrical activity of midbrain dopaminergic neurons.

1 reference

12 December 2020

Atypical antipsychotics and weight gain--a systematic review

1 reference

12 December 2020

Treatment programme and long-term outcome in chronic schizophrenia

1 reference

12 December 2020

Clinical advantages of amisulpride in the treatment of acute schizophrenia

1 reference

12 December 2020

Atypical neuroleptics: a new approach in the treatment of negative symptoms

1 reference

12 December 2020

Safety of amisulpride (Solian): a review of 11 clinical studies

1 reference

12 December 2020

Health care expenditure on schizophrenia patients in Belgium

1 reference

12 December 2020

Schizophrenia: its etiology and impact

1 reference

12 December 2020

Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine

1 reference

12 December 2020

Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications

1 reference

12 December 2020

[Evaluation of efficacy and tolerance of amisulpride in treatment of schizophrenic psychoses]

1 reference

12 December 2020

Medico-economic assessment of neuroleptics in schizophrenia. Amisulpride versus haloperidol

1 reference

12 December 2020

Negative symptoms in schizophrenia: considerations for clinical trials. Working group on negative symptoms in schizophrenia

1 reference

12 December 2020

Costs of schizophrenia in The Netherlands

1 reference

12 December 2020

Acute antagonism of dopamine D2-like receptors by amisulpride: effects on hormone secretion in healthy volunteers

1 reference

12 December 2020

Do negative symptoms respond to pharmacological treatment?

1 reference

12 December 2020

Costs of services for schizophrenic patients in Norway.

1 reference

12 December 2020

New antipsychotic agents: emerging clinical profiles

1 reference

12 December 2020

A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers

1 reference

12 December 2020

The effect of neuroleptics on cognitive and psychomotor function

1 reference

12 December 2020

Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association

1 reference

12 December 2020

Efficacy and safety of novel antipsychotics: a critical review

1 reference

12 December 2020

The diagnosis and understanding of schizophrenia. Part III. Speculations on the processes that underlie schizophrenic symptoms and signs.

1 reference

12 December 2020

Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group

1 reference

12 December 2020

Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia

1 reference

12 December 2020

1 reference

12 December 2020

Potentiation by low doses of selected neuroleptics of food-induced conditioned place preference in rats.

1 reference

12 December 2020

Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group

1 reference

12 December 2020

Antipsychotic-induced weight gain: a comprehensive research synthesis

1 reference

12 December 2020

Drug treatments for schizophrenia

1 reference

12 December 2020

Psychopharmacologic treatment of negative schizophrenic symptoms

1 reference

12 December 2020

Deficit and nondeficit forms of schizophrenia: the concept

1 reference

12 December 2020

Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity

1 reference

12 December 2020

Single oral doses of amisulpride do not enhance the effects of alcohol on the performance and memory of healthy subjects.

1 reference

12 December 2020

Late-onset schizophrenia: epidemiology, diagnosis, management and outcomes

1 reference

12 December 2020

Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia.

1 reference

12 December 2020

The effects of neuroleptics on neuropsychological test results of schizophrenics.

1 reference

12 December 2020

Costs of schizophrenia

1 reference

12 December 2020

Economics and schizophrenia: the real cost

1 reference

12 December 2020

Treatment of negative symptoms in schizophrenia with amisulpride

1 reference

12 December 2020

Evaluating the effects of antipsychotics on cognition in schizophrenia. Collaborative Working Group on Clinical Trial Evaluations

1 reference

12 December 2020

A comparative review of new antipsychotics

1 reference

12 December 2020

One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol

1 reference

12 December 2020

Improvement of some schizophrenic deficit symptoms with low doses of amisulpride

1 reference

12 December 2020

Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients

1 reference

12 December 2020

Effects of 50mg amisulpride on EEG, psychomotor and cognitive functions in healthy sleep-deprived subjects

1 reference

12 December 2020

The new antipsychotics, and their potential for early intervention in schizophrenia

1 reference

12 December 2020

Psychomotor, Cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic

1 reference

12 December 2020

Biotransformation of Post-Clozapine Antipsychotics

1 reference

12 December 2020

Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group

1 reference

12 December 2020

From pharmacological profiles to clinical outcomes

1 reference

12 December 2020

Amisulpride: from animal pharmacology to therapeutic action

1 reference

12 December 2020

The acute effects of amisulpride (50 mg and 200 mg) and haloperidol (2 mg) on cognitive function in healthy elderly volunteers

1 reference

12 December 2020

Guidelines for the use of antipsychotic drug studies in healthy volunteers. The BAP Consensus Group

1 reference

12 December 2020

Assessing the efficacy of treatments for the deficit syndrome of schizophrenia

1 reference

12 December 2020

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

1 reference

12 December 2020

10.2165/00003495-200161140-00014

Identifiers

DOI

1 reference

Dimensions Publication ID

2 August 2017

1023550948

0 references

1 reference